Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome

British Journal of Cancer

Volumn 78, Issue 5, 1998, Pages 621-624

  Bincoletto, C ^a   Saad, S T O ^a   Soares Da Silva, E ^a   Queiroz, M L S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Apoptosis; Autonomous cell proliferation; bcl 2; Myelodysplastic syndrome

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031902684     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.551     Document Type: Article

References (40)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR and Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199
2. Bogdanovic AD, Trpinac DP, Jankovick GM, Bumbasirevic VZ, Obradovic M and Colovic MD (1997) Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 11: 655-659
3. Bradbury DA and Russell NH (1995) Comparative quantitative expression of Bcl-2 by normal and leukaemic myeloid cells. Br J Haematol 91: 374-379
4. Bradbury D, Zhu YM and Russell N (1994) Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 8: 786-791
5. Clark DM and Lampert IA (1990) Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma 2:415-418
6. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA and Della Porta G (1992) Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79: 1291-1298
7. Fenaux P (1996) Myelodysplastic syndromes. Hematol Cell Ther 38: 363-380
8. Gajewaki TF and Thompson CB (1996) Apoptosis meets signal transduction: elimination of a BAD influence. Cell 87: 589-592
9. Ganser A and Hoelzer D (1992) Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol-Oncol Clin N Am 6: 633-653
10. Green DR, Bissonnette RP and Cotter TG (1994) Apoptosis and cancer. Princ Pract Oncol Updates 8: 1
11. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097
12. Hockenbery DM, Zutter M, Hickley W, Nahm M and Korsmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965
13. Hoefsloot LH, van Amelsvoort MP, Breeders LCAM, Van der Plas DC, Van Lom K, Hoogerbrugge H, Touw IP and Löwenberg B (1997) Erythropoietin-induced activation of stat5 is impaired in the myelodysplastic syndrome. Blood 89: 1690-1700
14. Hu ZB, Minden MD and McMulloch EA (1996) Post-transcriptional regulation of Bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Leukemia 10: 410-416
15. Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT and Lewis T (1989) Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Hematol 73: 36-39
16. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y and Cossman J (1993) Bcl-2 protein inhibits etoposide-induced apoptosis through its effects subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53: 4251-4256
17. Karawajew L, Wuchter C, Rupper V, Drexler H, Gruss HJ, Dörken B and Ludwig WD (1997) Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 11:1245-1252
18. Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886
19. Koshida Y, Saegusa M and Okayasy I (1997) Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 75: 367-373
20. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 6: 614-619
21. Lepelley P, Soenen V, Preudhomme C, Merlat A, Cosson A and Fenaux P (1995) Bcl-2 expression in myelodysplastic syndromes and its correlation with haematological features, p53 mutations and prognosis. Leukemia 9: 726-730
22. Loffler H, Schmitz N and Gassmann W (1992) Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol-Oncol Clin Am 6: 619-631
23. Metcalf D (1984) The biossay of colony stimulating factors. In The Hemopoietic Colony Stimulating Factors, Metcalf D (ed) pp. 187-212. Elsevier: Amsterdam
24. Miyashita T, Harigai M, Hanada M and Reed JC (1994) Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 54: 3131-3135
25. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ and Hall AG (1994) The relationship between Bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 88: 105-109
26. Munker R, Midis G, Owen-Schaub L and Andreff M (1996) Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 10: 1531-1533
27. Nowak R (1992) Dying cells reveal new role for cancer genes. J NIH Res 4: 48-52
28. Rapajaksa R, Ginzton N, Rott LS and Greenberg PL (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88: 4275-4287
29. Raza A, Gezer S, Mundle S, Gao X, Alvi S, Borok R, Rifkin S, Iftikhar VS, Parcharidou A, Lowe J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S and Preisler H (1995) Apoptosis in bone marrow biopsy samples involving stromal and haemopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86: 268-276
30. Russell NH, Hunter AE, Bradbury D, Zhu YM and Keith F (1995) Biological features of leukaemia cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk-Lymp 16: 223-229
31. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C and Raza A (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Res 20: 891-900
32. Silva ES, Lorand-Metze I, Bincoletto C and Saad STO (1997) Patterns of expression of Ras, P53 and MDM2 proteins in myelodysplastic syndromes. Leukemia Res 21 (Suppl. 1): 143a, 537
33. Soligo DA, Campiglio S, Servida F, Bossolasco P, Romitti L, Cortelezzi A and Lambertenghi Deliliers G (1996) Response of myelodysplastic syndrome marrow progenitor cells to stimulation with cytokine combinations in a stroma-free long-term culture system. Br J Haematol 92: 548-558
34. Vaux DL (1993) Toward an understanding of the molecular mechanisms of physiologic cell death. Proc Natl Acad Sci USA 90: 786-789
35. Young DC and Griffin JD (1986) Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 68: 1178-1181
36. Vaux DL, Cory S and Adams JM (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442
37. Willemze R, Fibbe WE, Falkenburg JHF, Kluin-Nelemans JC, Kluin PM and Landegent JE (1993) Biology and treatment of myelodysplastic syndromes - developments in the past decade. Ann Haematol 66: 107-115
38. Yoshida Y (1993) Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 7: 144-146
39. Yoshida Y, Anzai N, Kawabata H (1995) Apoptosis in myelodysplasia: a paradox or paradigma. Leuk Res 19: 887-891
40. Young DC and Griffin JD (1986) Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 68: 1178-1181